Health and Healthcare

Opko Settles Fraud Charges With SEC: Good News for Investors?

Opko Health Inc. (NASDAQ: OPK) shares shot up on Friday after the firm announced that it has settled with the U.S. Securities and Exchange Commission (SEC). Both parties have agreed to resolve the action brought against Opko’s board chair and chief executive, Dr. Phillip Frost.

Without admitting or denying the SEC’s allegations, Opko agreed to an injunction from certain violations of the Securities Exchange Act of 1934. Opko has agreed to pay a $100,000 penalty and will perform certain undertakings related to the Securities Exchange Act.

Separately, Frost agreed, without admitting or denying the SEC’s allegations, to injunctions from certain violations of the Securities Act of 1933 and the Securities Exchange Act. He also agreed to pay approximately $5.5 million in penalty, disgorgement and prejudgment interest. There is also a prohibition, with certain exceptions, from trading in penny stocks.

Frost commented:

We have reached agreement with the SEC that will end a potentially expensive, contentious and time-consuming litigation and I am happy that we can focus on an exciting and productive 2019 for OPKO Health.

Shares of Opko were last seen up 13% at $2.86, with a 52-week range of $2.33 to $6.40. The stock has a consensus analyst price target of $10.00.

Smart Investors Are Quietly Loading Up on These “Dividend Legends” (Sponsored)

If you want your portfolio to pay you cash like clockwork, it’s time to stop blindly following conventional wisdom like relying on Dividend Aristocrats. There’s a better option, and we want to show you. We’re offering a brand-new report on 2 stocks we believe offer the rare combination of a high dividend yield and significant stock appreciation upside. If you’re tired of feeling one step behind in this market, this free report is a must-read for you.

Click here to download your FREE copy of “2 Dividend Legends to Hold Forever” and start improving your portfolio today.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.